Dual C20 Fatty Acid-Conjugated Insulin Analog LPJT-026: Enhanced HSA Binding, Prolonged PK/PD Profiles, and Reduced Hypoglycemia Risk for Biweekly Diabetes Therapy
Pharmaceutical Research · 2026
DOI: 10.1007/s11095-026-04166-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Research, 2026. Verfasst von Yiwei Tou und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Chemical Engineering, Beijing Institute of Technology, Beijing, 100081, China. Hauptthemen laut MEDLINE: Hypoglycemia, Diabetes Mellitus, Experimental, Hypoglycemic Agents, Fatty Acids. Die Arbeit nennt 32 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
PURPOSE: This research aimed to develop a next-generation ultra-long-acting insulin analog with dual long-chain fatty acid conjugation, addressing unmet needs of frequent injections and hypoglycemia risk in diabetes therapy. METHODS: LPJT-026, a dual C20 fatty acid-modified insulin (LysA22 and LysB29), was designed, synthesized and characterized. Head-to-head comparisons with marketed insulin icodec (Awiqli®) were performed via in vitro binding assays (HSA/INSR/IGF-1R) and in vivo PK/PD evaluations in STZ-induced type 1 diabetic (T1D) rats and Beagle dogs. Long-term efficacy (HbA1c reduction) and safety (hypoglycemia-related mortality) were assessed in 8-week repeated-dose studies. RESULTS: LPJT-026 (purity ≥ 98%) bears C20 fatty acid chains at LysA22 and LysB29, exhibiting significantly higher human serum albumin (HSA) binding affinity (KD = 139 nM vs. 510 nM for Insulin Icodec) and favorable insulin receptor binding (KD = 134 nM). Animal studies demonstrated superior PK/PD profiles: LPJT-026 sustained glucose-lowering effects for 96 h (vs. 72 h for Insulin Icodec) with significantly lower hypoglycemia-related mortality (10% vs. 40%, p 373 min) supporting translational potential. CONCLUSIONS: Dual fatty acid conjugation enables LPJT-026 to form a stable HSA-binding reservoir, achieving biweekly dosing potential, superior glycemic control, and improved safety. LPJT-026 represents a promising next-generation therapy for insulin-dependent diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemistry and Chemical Engineering, Beijing Institute of Technology, Beijing, 100081, China.
- School of Chemistry and Chemical Engineering, Chongqing University of Science and Technology, Chongqing, 401331, China.
- School of Chemistry and Chemical Engineering, Beijing Institute of Technology, Beijing, 100081, China. yhz@bit.edu.cn.
Zitieren
APA
Tou, Y., Luo, J., Sun, J., Liu, P., Huang, Q., & Zhang, Y. H. (2026). Dual C20 Fatty Acid-Conjugated Insulin Analog LPJT-026: Enhanced HSA Binding, Prolonged PK/PD Profiles, and Reduced Hypoglycemia Risk for Biweekly Diabetes Therapy. Pharmaceutical Research. https://doi.org/10.1007/s11095-026-04166-5
Vancouver
Tou Y, Luo J, Sun J, Liu P, Huang Q, Zhang YH. Dual C20 Fatty Acid-Conjugated Insulin Analog LPJT-026: Enhanced HSA Binding, Prolonged PK/PD Profiles, and Reduced Hypoglycemia Risk for Biweekly Diabetes Therapy. Pharmaceutical Research. 2026. doi:10.1007/s11095-026-04166-5
BibTeX
@article{Tou2026,
author = {Tou, Yiwei and Luo, Jihong and Sun, Jiuyi and Liu, Pai and Huang, Qishen and Zhang, Yun-Hong},
title = {Dual C20 Fatty Acid-Conjugated Insulin Analog LPJT-026: Enhanced HSA Binding, Prolonged PK/PD Profiles, and Reduced Hypoglycemia Risk for Biweekly Diabetes Therapy},
journal = {Pharmaceutical Research},
year = {2026},
doi = {10.1007/s11095-026-04166-5}
}
EUVIMED